|
|
|
| Effects of curcumin derivative WZ01 on asthmatic airway inflammatory mediators IL-13, histamine and glucocorticoid receptor |
| LI Yuan1, ZHAN Meizheng1, YE Leping1, GE Renshan2,LI Changchong1 |
1.Department of Pediatric Pulmonology, the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, 325027; 2.Research Center, the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, 325027
|
|
| Cite this article: |
|
LI Yuan,ZHAN Meizheng,YE Leping, et al. Effects of curcumin derivative WZ01 on asthmatic airway inflammatory mediators IL-13, histamine and glucocorticoid receptor[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(7): 497-502.
|
|
|
Abstract Objective: To investigate the effects of curcumin derivative WZ01 on asthmatic airway inflammation, inflammatory mediators IL-13 and histamine, and glucocorticoid receptor (GR). Methods: Thirty mice were randomly divided into: control group, asthma group, low dose WZ01 group, moderate dose WZ01 group and high dose WZ01 group. Each group was 6 mice, respectively. After sensitized with OVA, the mice were challenging with 1% OVA from the 21th to 27th day. Each mouse was intraperitoneally injected with corresponding drugs or normal saline half an hour before atomizing. After the last challenging, mice were anesthetized and sacrificed within 24 hours, lung tissues were obtained for detecting inflammatory alteration with hematoxylin-eosin staining, and the BALF for cellular classification and counting and the concentrations of IL-13 and histamine by ELISA assay, the expression of GR in lung tissues was detected with immumohistochemical staining and Western blot. Results: Compared with the normal control group, HE staining showed massive inflammatory cellular infiltration and mucous secretion accumulated in the asthma group, ELISA analysis showed significantly increased number of inflammatory cells and concentrations of IL-13 and histamine in the BALF (P<0.01). Compared with the asthma group, each dose of WZ01 markedly inhibited the inflammatory cellular infiltration and mucous secretion in the airway; In each dose WZ01 group, the number of lymphocytes and eosinophils in BALF were distinctly decreased (P<0.01), accompanied by the remarkable decline of the concentrations of IL-13 and histamine (P<0.01); the number of lymphocytes had remarkably positive relationships with the concentrations of IL-13 and histamine in the BALF (r values were 0.886 and 0.886, respectively, P<0.01). The number of esoinophils had also remarkably positive relationships with the concentrations of IL-13 and histamine in the BALF (r values were 0.897 and 0.898, respectively, P<0.01). The results of immumohistochemical staining and Western blot showed that GR expression in the lung tissues of asthmatic mice was decrease. Compare with the asthma group, different doses of WZ01 could predominantly reverse and up-regulate the expression of GR in the lung tissues of asthmatic mice. Conclusion: WZ01 can significantly inhibit the inflammatory cellular infiltration and mucus secretion in asthma, which may be attributable to the decline of the inflammatory mediators IL-13 and histamine and the up-regulated expression of GR in the lung tissues of asthmatic mice. WZ01 may be a new drug of prevention and treatment for airway inflammation in asthma.
|
|
Received: 31 January 2016
|
| |
|
|
|
|
|
|
